Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

JPMorgan, Goldman Sachs delay workers' return to U.K. offices

Published 06/16/2021, 04:57 PM
Updated 06/16/2021, 05:04 PM
© Reuters. FILE PHOTO: A sign is seen on the Canary Wharf offices of JP Morgan in London September 19, 2013. REUTERS/Neil Hall

By Elizabeth Dilts Marshall

NEW YORK (Reuters) - Global banks JPMorgan Chase & Co (NYSE:JPM) and Goldman Sachs are delaying plans for workers to return to U.K. offices after the government extended its COVID-19 restrictions until mid-July due to the rapid spread of the more infectious Delta variant.

Goldman Sachs Group Inc (NYSE:GS), which required most U.S. staff to return to offices this week, told U.K. staff on Tuesday that working at its London office will remain voluntary for now, according to a memo seen by Reuters. Social distancing and mask-wearing is required, while the broader return to office plans are postponed until July, the bank said.

JPMorgan Chase & Co, which is requiring the majority of U.S. staff to return next month, notified U.K.-based employees that its broad return-to-office plans are on hold until July, according a memo to its staff.

The investment banks had planned to bring more staff back to offices--on a rotational basis, subject to a 50% occupancy cap--on some of the quickest timelines.

For both banks, roughly 20-30% of staff had been working in offices for several months, which allowed them to work out social distancing and health check protocols.

But the U.K. said delaying full reopening until July 19 will allow it to get more people fully vaccinated. Currently, about 41 million people have received their first shot and nearly 30 million have had both doses - about 57% of the adult population.

The majority of Goldman Sachs employees have "either had their first dose (of the vaccine) or expect to receive it before Monday, 21 June," Richard Gnodde, head of Goldman Sachs International, wrote in his memo to staff.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Studies on Monday showed the Delta variant doubles the risk of hospitalization, but two doses of vaccines made by Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN) offer more than 90% protection against hospitalization.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.